David J. Graham, MD, MPH

Associate director
US Food and Drug Administration

Poster(s):

• (067) Risk of Incident Inflammatory Bowel Disease in New Users of Dipeptidyl Peptidase 4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors in the FDA Sentinel System
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (119) Performance of the US Food and Drug Administration’s COVID-19 Disease Severity Categorization for Use in Real-World Data
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (127) Risk factors for severe outcomes among patients hospitalized with COVID-19 in US Medicare between December 2020 and March 2023
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (222) Medically-attended cannabis-related disorders among U.S. Medicare beneficiaries, 2017–2022
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (ASPOT01) Validity of the ICD-10-CM diagnosis code to identify patients with COVID-19 in Medicare administrative claims data
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST